Triveni Bio Doses First Healthy Volunteers with Next-Generation Bispecific Antibody TRIV-573 Targeting Kallikreins 5 & 7 and Interleukin 13 in Phase 1 Clinical Trial

B      — Dual mechanism uniquely combines barrier repair (KLK5/7) and established anti-inflammatory blockade (IL-13) to bring a first-in-class therapeutic to patients in atopic dermatitis…
posteditor
posteditor
Articles: 21727

Other News